Journal of Clinical Oncology, Vol 5, 1822-1826, Copyright © 1987 by American Society of Clinical Oncology

ARTICLES

Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes

MR O'Donnell, AP Nademanee, DS Snyder, GM Schmidt, PM Parker, PJ Bierman, JL Fahey, AS Stein, RA Krance and AD Stock
City of Hope National Medical Center, Duarte, CA 91010.

Twenty patients (age range, 4 to 48 years; median age, 36 years) with de novo or drug-induced myelodysplastic syndromes or myeloproliferative disorders were treated with myeloablative immunosuppressive therapy followed by bone marrow transplantation (BMT). Four preparative regimens were used; three regimens consisted of combined total body irradiation (TBI) and chemotherapy and one of combination chemotherapy only. One patient received marrow from his identical twin brother, whereas the other 19 patients were grafted with marrow from histocompatible siblings. In 19 patients the abnormal clone was at least temporarily ablated, while in one patient the congenital myelodysplasia persisted. Eight patients are alive and well for +108 to +3,359 days post-transplantation. Nine patients died of transplant- related complications (six of interstitial pneumonia, two of gastrointestinal bleeding, and one of fungal sepsis) and three patients died with persisting or recurring disease. One patient with a late recurrence has undergone a second successful bone marrow transplant procedure. Outcome of BMT was not related to French-American-British (FAB) type, marrow fibrosis, cytogenetic abnormalities, or preparation regimen. Marrow transplantation as a means of providing long-term disease-free survival and possible cure should be considered in patients if a suitable donor is available.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				L. Fouillard, M. Labopin, N.-C. Gorin, E. Polge, H. G. Prentice, G. Meloni, J. Reiffers, A. Pigneux, R. Willemze, A. Schattenberg, et al. Hematopoietic stem cell transplantation for de novo erythroleukemia: a study of the European Group for Blood and Marrow Transplantation (EBMT) Blood, October 16, 2002; 100(9): 3135 - 3140. [Abstract] [Full Text] [PDF]

				P. Guardiola, J. E. Anderson, G. Bandini, F. Cervantes, V. Runde, W. Arcese, A. Bacigalupo, D. Przepiorka, M. R. O'Donnell, P. Polchi, et al. Allogeneic Stem Cell Transplantation for Agnogenic Myeloid Metaplasia: A European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study Blood, May 1, 1999; 93(9): 2831 - 2838. [Abstract] [Full Text] [PDF]

				B. D. Cheson The Myelodysplastic Syndromes Oncologist, February 1, 1997; 2(1): 28 - 39. [Abstract] [Full Text] [PDF]

				J. O. Armitage Bone Marrow Transplantation N. Engl. J. Med., March 24, 1994; 330(12): 827 - 838. [Full Text]

				B. D. Cheson The Myelodysplastic Syndromes: Current Approaches to Therapy Ann Intern Med, June 15, 1990; 112(12): 932 - 941. [Abstract] [PDF]

				F. R. Appelbaum, J. Barrall, R. Storb, L. D. Fisher, G. Schoch, R. E. Ramberg, H. Shulman, C. Anasetti, S. I. Bearman, P. Beatty, et al. Bone Marrow Transplantation for Patients with Myelodysplasia: Pretreatment Variables and Outcome Ann Intern Med, April 15, 1990; 112(8): 590 - 597. [Abstract] [PDF]